Dear Member of Congress:

We urge you to reject efforts to pass H.R. 3, the Lower Drug Costs Now Act. This legislation imposes new taxes and government price controls on American medical innovation. It creates a 95 percent excise tax on manufacturers and imposes an international reference pricing scheme that directly imports foreign price controls into the U.S. This proposal will harm American patients and degrade America’s world-leading role in medical innovation.

Americans have access to several highly effective COVID-19 vaccines because of our cutting-edge medical innovation. Our success in COVID treatments and vaccines should serve as a reminder of why we must protect medical innovation here.

H.R. 3 would impose price controls from socialized medicine systems. Countries like Australia, the United Kingdom, and Canada would be able to dictate the terms of the American marketplace for medicines. Our patients and innovative research and development would pay the price.

H.R. 3 would weaponize the tax code and enact a discriminatory 95 percent excise tax on manufacturers. Under the legislation, pharmaceutical manufacturers that do not agree to foreign price controls would face a retroactive tax of up to 95 percent on the total sales of a drug (not net profits).

This means that a manufacturer selling a medicine for $100 will owe $95 in tax for every product sold with no allowance for the costs incurred. No deductions would be allowed, and it would be imposed on manufacturers in addition to federal and state income taxes they must pay.

This package of foreign price controls with a punitive excise tax on medicines will harm American patients by limiting access to new cures. Countries like Australia, the United Kingdom, and Canada often have to wait years before accessing the same treatments Americans get right away.

According to a study by the Galen Institute, patients in the U.S. had access to nearly 90 percent of new medical substances launched between 2011 and 2018. By contrast, other developed countries had a fraction of these new cures. Patients in the United Kingdom had 60 percent of new substances, Japan had 50 percent, Canada had 44 percent, and Spain had 14 percent. In many cases, Americans are able to buy less expensive generics before countries with socialized medicine can even access the underlying new medicines.
H.R. 3 will threaten high-paying manufacturing jobs across the country at a time when we are just emerging from the economic wreckage from the pandemic. According to a [2017 study](#) by TEConomy Partners, pharmaceutical manufacturers invest $100 billion in the U.S. economy every year, directly supporting 800,000 jobs including jobs in every state. These jobs are high-paying – the average compensation is $126,000 – more than double the average wage in the U.S. When accounting for indirect and induced jobs, medical innovation supports more than four million jobs.

The need for free market policies that promote American medical innovation is clear now more than ever. Thanks to American ingenuity, some of the most effective vaccines in history have been developed to fight the Coronavirus pandemic, at the fastest rates ever. In fact, vaccines developed by Pfizer and Moderna are both over 90 percent effective– a groundbreaking improvement over the typical flu vaccine, for example, which is [40 to 60 percent effective](#).

Far-left politicians are committed to imposing socialist policies on the entire American healthcare system. Price controls on medicines are just the first step.

We urge you to reject any effort to impose H.R. 3—in part or in full—as a part President Biden’s next spending plan. New taxes and price controls on medical innovation will reduce access to new cures and threaten high-paying manufacturing jobs across the country.

Sincerely,

Grover Norquist  
President, Americans for Tax Reform

Saulius “Saul” Anuzis  
President, 60 Plus Association

Jim Martin  
Founder/Chairman, 60 Plus Association

Marty Connors  
Chair, Alabama Center-Right Coalition

Phil Kerpen  
President, American Commitment

Brent Wm. Gardner  
Chief Government Affairs Officer, Americans for Prosperity

Dee Stewart  
President, Americans for a Balanced Budget

Richard Manning  
President, Americans for Limited Government
Tom Giovanetti  
President, Americans for a Strong Economy

Tom DeWeese  
President, American Policy Center

Dick Patten  
President, American Business Defense Council

Michael Bowman  
President, ALEC Action

Krisztina Pusok, Ph. D.  
Director, American Consumer Institute Center for Citizen Research

Bob Carlstrom  
President, AMAC Action

John Toedtman  
Executive Director, Caesar Rodney Institute

Rabbi Aryeh Spero  
President, Caucus for America

Ryan Ellis  
President, Center for a Free Economy

Andrew F. Quinlan  
President, Center for Freedom and Prosperity

Jeffrey Mazzella  
President, Center for Individual Freedom

Ginevra Joyce-Myers  
Executive Director, Center for Innovation and Free Enterprise

Peter Pitts  
President, Center for Medicine in the Public Interest

Regina Thomson  
President, Colorado Issues Coalition

Gregory Conko  
Senior Fellow, Competitive Enterprise Institute

Chuck Muth  
President, Citizen Outreach

Ashley Baker  
Director of Public Policy, The Committee for Justice

Matthew Kandrach  
President, Consumer Action for a Strong Economy
Yaël Ossowski  
Deputy Director, Consumer Choice Center

James Edwards  
Executive Director, Conservatives for Property Rights

Tom Schatz  
President, Council for Citizens Against Government Waste

Katie McAuliffe  
Executive Director, Digital Liberty

Robert Roper  
President, Ethan Allen Institute

Adam Brandon  
President, FreedomWorks

George Landrith  
President, Frontiers of Freedom

Naomi Lopez  
Director of Healthcare Policy, Goldwater Institute

J. Scott Moody  
CEO, Granite Institute

Ron Williamson  
President, Great Plains Public Policy Institute

Garrett Bess  
Vice President, Heritage Action for America

Charles Sauer  
President, Market Institute

Heather R. Higgins  
CEO, Independent Women's Voice

Bartlett Cleland  
Executive Director, Innovation Economy Institute

Andrew Langer  
President, Institute for Liberty

Sal Nuzzo  
Vice President of Policy, James Madison Institute

Becki Gray  
Senior Vice President, John Locke Foundation (North Carolina)
Seton Motley  
President, Less Government

Mary Adams  
Chair, Maine Center-Right Coalition

Matthew Gagnon  
President, Maine Policy Institute

Christopher B. Summers  
President & CEO, Maryland Public Policy Institute

Rodolfo E. Milani  
Chairman, Miami Freedom Forum

Gene Clem  
Spokesman, Michigan Tea Party Alliance

Tim Jones  
Chair, Missouri Center-Right Coalition  
Fmr. Speaker, Missouri House of Representatives

Pete Sepp  
President, National Taxpayers Union

John Tsarpalas  
President, Nevada Policy Research Institute

Stephen Stepanek  
Chair, New Hampshire Center-Right Coalition

Douglas Kellogg  
Executive Director, Ohioans for Tax Reform

Tom Hebert  
Executive Director, Open Competition Center

Sally Pipes*  
President and CEO, Pacific Research Institute

Wayne Winegarden*  
Director of the Center for Medical Economics and Innovation, Pacific Research Institute

Joshua Crawford  
Executive Director, Pegasus Institute

Stone Washington  
Member, Project 21

Lorenzo Montanari  
Executive Director, Property Rights Alliance
Bette Grande  
President & CEO, Roughrider Policy Center

James L. Setterlund  
Executive Director, Shareholder Advocacy Forum

Karen Kerrigan  
President & CEO, Small Business & Entrepreneurship Council

Kerri Toloczko  
Chair, SW FL Center-Right Coalition

David Miller  
Chair, SW Ohio Center-Right Coalition

Paul E. Vallely, Major General, US Army (ret)  
Chairman, Stand Up America US Foundation

David Williams  
President, Taxpayers Protection Alliance

Kent Kaiser  
Executive Director, Trade Alliance to Promote Prosperity

C. Preston Noell III  
President, Tradition, Family, Property, Inc.

Bill Greener III  
President and Principal Spokesperson, United Seniors for America

Casey Given  
President, Young Voices

*Individuals listed for identification purposes only.